| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 30 Jan 2026 | 19 Jan 2026 |
| Quarterly Results Glenmark Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/01/2026 ,inter alia, to consider and approve the Unaudited Financial Results of the Company for the Third Quarter and Nine Months ended December 31, 2025. Pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that the Board at its meeting held today has approved the unaudited financial results for the Third Quarter and Nine Months ended 31st December, 2025 (As Per BSE Announcement Dated On : 30.01.2026) | ||
| Board Meeting | 14 Nov 2025 | 3 Nov 2025 |
| Glenmark Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2025 inter alia to consider and approve the Unaudited Financial Results of the Company for the second quarter and half year ended September 30 2025 Pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that the Board at its meeting held today has approved the unaudited financial results for the Second Quarter and Half Year ended 30th September, 2025. (As Per BSE Announcement Dated on 14.11.2025) | ||
| Board Meeting | 26 Sep 2025 | 22 Sep 2025 |
| Glenmark Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/09/2025 inter alia to consider and approve payment of interim dividend if any on Equity Shares of the Company for the financial year 2025-26. Outcome Of The Board Meeting Held On 26Th September, 2025 The Board approved Interim Dividend of Rs. 2.50 per equity shares on face value of Re. 1/- per equity shares for the Financial Year 2025-26 and reconstitution of Committees. (As Per BSE Announcement Dated on 26.09.2025) | ||
| Board Meeting | 14 Aug 2025 | 4 Aug 2025 |
| Glenmark Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2025 inter alia to consider and approve the Unaudited Financial Results of the Company for the First Quarter ended June 30 2025. Please find attached herewith Unaudited Financial Results for the first quarter ended 30th June, 2025 (As Per BSE Announcement Dated on: 14.08.2025) | ||
Revenue from North America increased 24% year on year to ₹970.6 crore, including income from the out licensing of ISB 2001.
Here are some of the stocks that may see significant price movement today: Polycab India, Tata Steel, Dalmia Bharat, etc.
Here are some of the stocks that may see significant price movement today: Glenmark Pharma, Rail Vikas Nigam, Birla Corp, etc.
At around 2.19 PM, Glenmark Pharma was trading 2.97% higher at ₹2,112.90 per piece, against the previous close of ₹2,051.90 on NSE.
Operating performance was slightly weaker, with EBITDA dipping 1.4% to ₹580 crore from ₹588.2 crore.
Here are some of the stocks that may see significant price movement today: Glenmark Pharmaceuticals, Vedanta, Inox Wind, etc.
The compound is currently in Phase 1B clinical trials, being studied for multiple myeloma, a tough-to-treat form of blood cancer.
Here are some of the stocks that may see significant price movement today: Tata Consultancy Services, IREDA, Glenmark Pharma, etc.
Here are some of the stocks that may see significant price movement today: Glenmark Pharma, Ashok Leyland, NTPC, etc.
ISB 2001 is a tri-specific antibody therapeutic for targeting BCMA and CD38 on myeloma cells, as well as CD3 on T cells.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
